
HEIDELBERG PHARMA AG
Acción · DE000A11QVV0 · A11QVV (XFRA)
4,28 EUR
13.06.2025 15:36
Cotizaciones actuales de HEIDELBERG PHARMA AG
Bolsa | Ticker | Moneda | Última operación | Precio | Variación diaria |
---|---|---|---|---|---|
![]() XETRA |
HPHA.DE
|
EUR
|
13.06.2025 15:36
|
4,28 EUR
| 4,73 EUR
-9,51 %
|
Rendimiento
Día | Semana | Mes | 3 meses | 6 meses | 1 año | 5 años |
---|---|---|---|---|---|---|
0,00 % | -9,89 % | 35,02 % | 65,89 % | 74,69 % | 49,65 % | 5,42 % |
Perfil de la empresa para HEIDELBERG PHARMA AG Acción
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; TAK-ATACs for oncology; and TLX250-CDx, a diagnostic antibody for imaging diagnostics of renal cancer in Phase III trials; urothelial carcinoma or bladder cancer in Phase I study; and triple-negative breast cancer in Phase II study. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.
Datos de la empresa
Nombre HEIDELBERG PHARMA AG
Empresa Heidelberg Pharma AG
Sitio web
https://heidelberg-pharma.com
Mercado principal
Frankfurt

WKN A11QVV
ISIN DE000A11QVV0
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Prof. Andreas Pahl
Capitalización de mercado 122 Mio
País Alemania
Moneda EUR
Empleados 0,1 T
Dirección Gregor-Mendel-Strasse 22, 68526 Ladenburg
Fecha de OPV 2006-11-13
Símbolos de cotización
Nombre | Símbolo |
---|---|
Frankfurt | HPHA.F |
XETRA | HPHA.DE |
Otras acciones
Los inversores que tienen HEIDELBERG PHARMA AG también tienen las siguientes acciones en su cartera:
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras.
Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.